HepQuant Completes Third State-Sponsored Grant
State of Colorado funding enables advancement of supply chain, regulatory advancements and HepQuant laboratory
DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that it has successfully fulfilled its objectives under the third grant received from the Colorado Office of Economic Development and International Trade (“OEDIT”).
Funding through Colorado OEDIT’s Advanced Industry Accelerator Grant Program is designed to accelerate commercialization, encourage public-private partnerships, increase access to early-stage capital and create a strong ecosystem that increases the state’s global competitiveness.
HepQuant Founder and Chief Executive Officer Dr. Gregory T. Everson noted, “HepQuant is quite pleased with the state’s commitment to advancing biotechnology. The funding support of OEDIT for this particular grant has enabled us to develop our supply chain for the HepQuant SHUNTTM Test Kits, obtain IDE approvals so that our tests can be used in Phase 2 and 3 drug trials, and establish our own laboratory at the BioScience II Building on the Anschutz Medical Campus.”
HepQuant obtained two earlier grants under the Bioscience Discovery Evaluation Grant Program (BDEGP) and Cash Fund which was first created by statute in 2006. The BDEGP program is continued under the new Advanced Industry Accelerator Program. The University of Colorado also received an additional grant from BDEGP to further the technology underlying the HepQuant SHUNTTM tests in studies there.
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
Tom Kennedy, Corporate Communications
Ph: (303) 548-3056